COMPANY PROFILE

Merida Biosciences

Explore full profile

Precision immunology leader developing targeted therapies for autoimmune and allergic disorders

Cambridge, United StatesFounded 2022Biotech & Life Sciences

Valuation $2.5–5B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Merida Biosciences

Merida Biosciences operates in the biopharmaceutical sector, focusing on precision immunology to address autoimmune and allergic disorders. The company aims to develop highly specific therapies that provide greater relief for patients, distinguishing itself from current treatments that are often non-specific and come with significant side effects. Merida's business model revolves around the discovery and development of these targeted therapies, serving patients suffering from autoimmune and allergic conditions. The company generates revenue through the commercialization of its therapies, leveraging the extensive experience of its leadership team in global biopharmaceutical operations and corporate development. Merida's market includes healthcare providers and patients seeking more effective and safer treatment options for autoimmune and allergic diseases. The leadership team, with a strong background in commercial operations and drug development, is well-positioned to drive the company's growth and achieve its vision of becoming a leader in precision immunology.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Cambridge, United States
Employees: 63
Open positions: 10
Dealroom signal: 60.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Immunotherapy, Biotech and Pharma, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Apr 2025	$121M	$484M	GV · Third Rock Ventures · BVF Partners · Bain Capital Life Sciences	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Merida Biosciences website traffic

Latest recorded traffic for Merida Biosciences is 5.8K monthly website visits, down 15.9% over the last three months.

Latest monthly visits5.8K 3-month web change-15.9%

Monthly website visitsApr 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Sr. Manager / Associate Director, Late-Phase Drug Substance PD/MSATLondon, United Kingdom, Northern Europe, Europe · Other · Aug 31, 2026 Associate Director/Director Drug Product DevelopmentLondon, United Kingdom, Northern Europe, Europe · Other · Aug 31, 2026 Scientist, Formulation DevelopmentLondon, United Kingdom, Northern Europe, Europe · Other · Aug 31, 2026 Sr. Manager / Associate Director, Late-Phase Drug Substance PD/MSATCambridge, MA · Other · Aug 11, 2026 Scientist, Formulation DevelopmentCambridge, MA · Other · Aug 10, 2026 Associate Director, Regulatory Affairs OperationsCambridge, Massachusetts, United States, Northern America, Americas · Other · Jul 6, 2026 Director, Medical WritingCambridge, MA · Other · Jun 24, 2026 Associate Director/Director Drug Product and Formulation DevelopmentLondon, United Kingdom, Northern Europe, Europe · Other · Jun 21, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OTOdyssey TherapeuticsBuilding a machine learning-based platform to develop novel therapeutics focusing on cancer and autoimmune diseases	Boston, United States	Operational	124	$792M	$983M
ATAntares TherapeuticsDevelopment of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments	Boston, United States	Operational
MTMirador TherapeuticsA next-generation precision medicine company focused on immunology and inflammation	San Diego, United States	Operational
PMPathCision MedicineDeveloping targeted therapies for complex diseases, with a primary focus on metastatic cancer	Watertown, United States	Operational
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational
ALAlumisDeveloping precision medicines for autoimmune diseases	South San Francisco, United States	Operational
HBHuman Immunology BiosciencesBiotechnology company focused on developing therapies for immune-mediated diseases	San Francisco, United States	Acquired
CTCrystalys TherapeuticsClinical-stage biopharmaceutical developing therapies for gout	San Diego, United States	Operational